MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Metformin (Glucophage®)

Selected References:

  • Abolhassani N. 2023. Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. BMJ Open Diab Res Care: 11(1).
  • Brand KM. 2022. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. BMJ Open Diab Res Care 10(1): e002363.
  • Brand KM. 2022. Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study. BMJ Open Diab Res Care: 10(6), e003056.
  • Briggs GG, et al. 2005. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol 105(6):1437-41.
  • Cassina M, et al. 2014. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 20(5):656-69.
  • Coetzee EJ, et al. 1980. Pregnancy in established non- insulin-dependent diabetics: A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 58:795-802.
  • Coetzee EJ, et al. 1984. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J. 65:635-7.
  • Dhulkotia JS, et al. 2010. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol. 203(5):457.e1-9.
  • Diav-Citrin O, et al. 2018. In-utero exposure to metformin for type 2 diabetes or polycystic ovary syndrome: A prospective comparative observational study. Reprod Toxicol. 80:85-91.
  • Feig DS, et al. 2007. Oral antidabetic agents in pregnancy & lactation: a paradigm shift? Ann Pharmacother 41:1174-80.
  • Feig DS et al. 2023. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol 11(3):191–202.
  • Fornes R, et al. Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. Reproductive Biology and Endocrinology, 20(1): 1-12.
  • Gardiner SJ, et al. 2003. Transfer of metformin into human milk. Clin Pharmacol Ther 73:71-7.
  • Ghazeeri G, et al. 2012. Pregnancy outcomes and effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstetricia et Gynecologica Scandinavica. 91:658–678.
  • Gilbert C, et al. 2006. Pregnancy outcome after first-trimester exposure of metformin: a meta-analysis. Fertil Steril 86:658-63.
  • Glueck CJ, et al. 2001. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46-52.
  • Glueck CJ, et al. 2002. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17:2858-64.
  • Glueck CJ et al. 2004. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 19:1323-30.
  • Glueck CJ et al. 2006. Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr 148:628-32.
  • Glueck CJ et al. 2008. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 89:625-634.
  • Glueck CJ et al. 2013. Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Current Med Res and Op. 29(1): 55-62.
  • Greger HK et al. 2020. Cognitive function in metformin exposed children, born to mothers with PCOS-follow-up of an RCT. BMC Pediatrics 20:60.
  • Ismail B, et al. 2019. Assessment of the fetal myocardial performance index in well‐controlled gestational diabetics & to determine whether it is predictive of adverse perinatal outcome. Pediatric Cardiology. 40:1460–1467.
  • Jakubowicz D. 2002. Effects of Metformin on Early Pregnancy Loss in the Polycystic Ovary Syndrome, J of Clinical Endocrinology & Metabolism 87(2): 524-529.
  • Meek CL. 2023. An unwelcome inheritance: childhood obesity after diabetes in pregnancy. Diabetologia, 66(11), 1961-1970.
  • Newman C. 2022. Metformin for pregnancy and beyond: the pros and cons. Diabetic Medicine 39(3): e14700.
  • Panchaud A, et al. 2018. Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. Br J Clin Pharmacol 84(3): 568-578.
  • Picon-Cesar MJ, et al 2021. Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. Am J Obstet Gyneol 225”517.e1-17.
  • Tarry-Adkins J, et al. 2019. Neonatal, infant, and childhood growth following metform versus insulin treatment for gestational diabetes: A systemic review and meta-analysis. PLOS Medicine 16(8): e1002848.
  • Tavlo M, et al. 2022. Hypothesis: Metformin is a potential reproductive toxicant. Frontiers in Endocrinology, 13: 2660.
  • Tosti G, et al. 2023. Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond. Frontiers in Endocrinology 14: 1176623.
  • Tseng CH. 2022. The effect of metformin on male reproductive function and prostate: An updated review. The World Journal of Men’s Health 40(1): 11.
  • Wensink MJ, Lu Y, Tian L, et al. Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study. Ann Intern Med. 2022;175(5):665-673.
  • Wouldes TA, et al. 2016 Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed 101(6):F488-F493.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.